Recursion’s SYCAMORE trial meets primary endpoint of safety and demonstrates encouraging trends in objective MRI-based exploratory efficacy measures SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading…
September 7th, 2024 Join us for a spectacular evening of music and unity with our nationally broadcast virtual concert, where artists will perform live to raise funds and awareness for…
Your generosity has made a difference! Get the full 2023 Impact Report here
We are excited to announce that we have updated our patient registry to a new platform! There are two options to create an account in our new registry: Patient account-this…
Join us at our 2024 Patient Conference on July 26th! You will have an opportunity to meet and mingle with patients, as well as learn from top CCM researchers. More…
